CHCut Nurul Hafifah

Cut Nurul Hafifah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cut Nurul Hafifah has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Genetic mutation patterns in Indonesian children with primary steroid–resistant nephrotic syndrome

    by Reza Fahlevi, Partini Pudjiastuti Trihono, Dina Muktiarti, Eka Laksmi Hidayati, Pustika Amalia Wahidayat, Cut Nurul Hafifah, Widya Eka Nugraha, Mentari Kasih

    Background Approximately 10–30% of pediatric cases of steroid-resistant nephrotic syndrome (SRNS) have pathogenic monogenic variants, particularly in primary SRNS. Identifying these variants aids in predicting outcomes, guiding treatment, and enabling genetic counseling. In Indonesia, data on genetic mutation patterns in pediatric SRNS are still limited. Methods A cross-sectional study was conducted using whole-exome sequencing (WES) to detect variants of genetic origin in children diagnosed with primary SRNS at Indonesia’s National Referral Hospital, Cipto Mangunkusumo. We assessed the relationship between genetic findings and clinical features, including age at onset, treatment response, kidney biopsy, and kidney function. Results Among 60 children with primary SRNS, 9 subjects (15%) harbored pathogenic or likely pathogenic variants across 8 genes (CUBN, AVIL, TRPC6, INF2, COL4A4, LAMA5, INVS, and FGA). Variants included stop-gained (n = 4), missense (n = 4), splice site (n = 1), and frameshift (n = 1), with both autosomal recessive and dominant inheritance observed. Two subjects had compound heterozygous variants. Most variant-positive subjects were male (6/9), had disease onset before age 3, and showed diverse histology (FSGS, MCD, or mesangial/membranoproliferative lesions). Four showed extrakidney features: peripheral neuropathy, high myopia, microcephaly with short stature, and hearing loss. While 53.3% responded to cyclosporin, over half remained in non-remission. Conclusions This study reveals the genetic and phenotypic heterogeneity of primary SRNS in Indonesian children. The identification of diverse pathogenic variants underscores the utility of WES, even in cases responsive to cyclosporin. Genetic testing should be integrated into routine SRNS evaluation, especially in atypical presentations or early-onset of the disease. Graphical Abstract A higher resolution version of the Graphical abstract is available as Supplementary information

  • Open Access

    Gastrointestinal Tolerance and Refeeding Syndrome in Severely Malnourished Children Treated with Oral Nutrition Supplements Compared to F-75/F-100: A Hospital-Based Randomized Controlled Pilot Trial

    by Klara Yuliarti, Lanny Christine Gultom, Cut Nurul Hafifah, Ina Susianti Timan, Merci Monica Boru Pasaribu, Ferry Liwang, Valensia Vivian The, Damayanti Rusli Sjarif

    Yuliarti K, et al. Pediatr Gastroenterol Hepatol Nutr. 2026 Mar;29(2):169-182. https://doi.org/10.5223/pghn.2026.29.2.169

  • Open Access

    Clinical phenotype and trio whole exome sequencing data from a patient with glycogen storage disease IV in Indonesia

    by Ivan William Harsono, Yulia Ariani, Beben Benyamin, Fadilah Fadilah, Dwi Ari Pujianto, Cut Nurul Hafifah, Titis Prawitasari


  • Open Access

    IDeRare: a lightweight and extensible open-source phenotype and exome analysis pipeline for germline rare disease diagnosis

    by Ivan William Harsono, Yulia Ariani, Beben Benyamin, Fadilah Fadilah, Dwi Ari Pujianto, Cut Nurul Hafifah

    Objectives: Diagnosing rare diseases is an arduous and challenging process in clinical settings, resulting in the late discovery of novel variants and referral loops. To help clinicians, we built IDeRare pipelines to accelerate phenotype-genotype analysis for patients with suspected rare diseases. Materials and Methods: IDeRare pipeline is separated into phenotype and genotype parts. The phenotype utilizes our handmade Python library, while the genotype part utilizes command line (bash) and Python script to combine bioinformatics executable and Docker image. Results: We described various implementations of IDeRare phenotype and genotype parts with real-world clinical and exome data using IDeRare, accelerating the terminology conversion process and giving insight on the diagnostic pathway based on disease linkage analysis until exome analysis and HTML-based reporting for clinicians. Conclusion: IDeRare is freely available under the BSD-3 license, obtainable via GitHub. The portability of IDeRare pipeline could be easily implemented for semi-technical users and extensible for advanced users.


  • Open Access

    The Effectiveness of Modified Atkins Ketogenic Diet on Children with Intractable Epilepsy: A Pilot Study from Indonesia

    by Achmad Rafli, Setyo Handryastuti, Mulya Rahma Karyanti, Yoga Devaera, Cut Nurul Hafifah, Irawan Mangunatmadja, Muzal Kadim, Elisabeth Siti Herini, Lora Sri Nofi, Ariek Ratnawati, et al.

    Background. The ketogenic diet has recently been explored as a potential treatment approach for intractable epilepsy in children and has been applied in various parts of the world. The ketogenic diet is also effective for the treatment of mood disorders, especially for adolescent and young adults with epilepsy. The Modified Atkins Diet (MAD) is the less restrictive type of ketogenic diet with similar principles as the classic type. However, no study has been conducted to evaluate the use of MAD in children with severe epilepsy in Indonesia. This study aims to assess the effectiveness, tolerance, compliance, and the adverse effects of MAD in children with intractable epilepsy during a 6-month monitoring period. Methods. This is a pilot experimental study involving children aged 2–18 years old with intractable epilepsy at the Pediatric Neurology and the Pediatric Nutrition & Metabolic Diseases Clinics at the Dr. Cipto Mangunkusumo Hospital Jakarta between November 2021 and June 2022. Results. A total of 31 subjects met the inclusion criteria and received the MAD in the first month, followed by 13 (41.9%) subjects in the third month, and 9 (29%) subjects in the sixth month. The MAD reduced the seizure frequency by 50% ( ), 62% ( ), and 83.3% ( ) in the first, third, and sixth months, respectively. The most frequent adverse effects are vomiting and diarrhea. Noncompliance was observed in 18 (58.1%) subjects. A sample of the MAD food menu guidebook was developed to make it easier for parents to adhere to the diet. Conclusions. The MAD reduces the mean seizure frequency in children with intractable epilepsy in the first, third, and sixth months, with a statistical significance in the sixth month. A further randomized, controlled, and multicenter clinical trial with a larger sample size and longer observation period is required. This trial is registered with Protocol ID 20-10-1323.